Corpus Intelligence IC Memo — HAMPTON HOSPITAL 2026-04-26 08:06 UTC
IC Memo — HAMPTON HOSPITAL
Investment Committee Memorandum | NJ | 120 beds | Grade C | EBITDA uplift $2.4M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

HAMPTON HOSPITAL

CCN 314021 | BURLINGTON, NJ | 120 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

HAMPTON HOSPITAL is a 120-bed suburban community hospital in BURLINGTON, NJ with $33.0M in net patient revenue and a 2.5% operating margin. The hospital serves a payer mix of 11.8% Medicare, 0.1% Medicaid, and 88.1% commercial.

Thesis: Undervalued. Our ML models identify $2.4M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from 2.5% to 9.8% (+736bps).

Net Revenue HCRIS$33.0M
Current EBITDA COMPUTED$810K
Operating Margin COMPUTED2.5%
Occupancy HCRIS78.6%
Revenue / Bed COMPUTED$275K
Net-to-Gross HCRIS49.2%
Distress Probability ML43.4%

2. Market Context & Competitive Position

95
NJ Hospitals
-3.9%
State Median Margin
52
Comparable Hospitals

NJ has 95 Medicare-certified hospitals with a median operating margin of -3.9%. The target's margin of 2.5% places it above the state median. Among 52 size-comparable peers (60-240 beds), the median margin is -8.2%. The target performs in line with or above peers.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (60-240), prioritizing same-state peers. 52 hospitals in the comp set.

HospitalStateBedsRevenueMargin
HAMPTON HOSPITAL (Target)NJ120$33.0M2.5%
CAPITAL HEALTH MED CENTER - HONJ209$746.8M0.8%
PRINCETON HEALTHCARE SYSTEMNJ206$587.8M-5.7%
MONMOUTH MEDICAL CENTERNJ240$448.7M-10.8%
HELENE FULD MEDICAL CENTERNJ162$430.2M-3.2%
HUNTERDON MEDICAL CENTERNJ184$358.4M-9.6%
CENTRASTATE MEDICAL CENTERNJ240$307.8M-23.2%
MOUNTAINSIDE HOSPITALNJ184$306.3M12.2%
ST. CLARES HOSPITALNJ217$291.4M-0.2%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $2.4M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$692K+210bp18mo
Cost to Collect4.5%2.5%$659K+200bp12mo
Denial Rate Reduction12.0%6.5%$652K+198bp12mo
A/R Days Reduction5200.0%3800.0%$401K+122bp9mo
Clean Claim Rate88.0%96.0%$21K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$692K
Cost to Collect
$659K
Denial Rate Reduction
$652K
A/R Days Reduction
$401K
Clean Claim Rate
$21K
Total EBITDA Uplift$2.4M
Current EBITDA$810K
+ RCM Uplift+$2.4M
Pro Forma EBITDA$3.2M
Current Margin2.5%
Pro Forma Margin9.8%
WC Released (1x)$1.3M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$1.2M$29.6M23.75x88.4%
Base (11x exit)10.0x11.0x$1.2M$33.0M26.44x92.5%
Bull Case9.0x11.0x$1.1M$41.4M36.88x105.8%
Bull (12x exit)9.0x12.0x$1.1M$45.5M40.53x109.7%
Bear Case11.0x10.0x$1.4M$17.1M12.45x65.6%
Bear (11x exit)11.0x11.0x$1.4M$19.2M14.02x69.6%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
MediumStandard execution riskRCM improvement requires management buy-in and 12-18 month implementation timeline

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 52 hospitals with 60-240 beds
  • Same-state prioritization (n=53)
  • Comp margins: P25=-25.6% / P50=-8.2% / P75=1.9%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.